[{"id":"61d86a30-55c7-41a4-bec4-37a547f93c03","acronym":"OP-1250-003","url":"https://clinicaltrials.gov/study/NCT05508906","created_at":"2022-08-19T17:10:19.756Z","updated_at":"2025-02-25T15:54:36.272Z","phase":"Phase 1","brief_title":"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus","source_id_and_acronym":"NCT05508906 - OP-1250-003","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-10-03"},{"id":"7d23d816-d6f4-41e9-9cb9-d2526c0cc2b3","acronym":"OPERA-01","url":"https://clinicaltrials.gov/study/NCT06016738","created_at":"2023-08-30T14:08:41.909Z","updated_at":"2024-07-02T16:34:59.724Z","phase":"Phase 3","brief_title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06016738 - OPERA-01","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-31"}]